Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2008

CERUS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   0-21937   68-0262011
(State of jurisdiction)   (Commission File No.)   (IRS Employer Identification No.)

2411 Stanwell Drive

Concord, California 94520

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (925) 288-6000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On June 11, 2008, Cerus Corporation (the “Company”) announced that its subsidiary, Cerus Europe B.V., entered into an agreement to supply the INTERCEPT Blood System for platelets to the largest group of blood centers of the German Red Cross, including the Frankfurt region. A copy of the Company’s press release, entitled “Cerus Enters Into Agreement to Supply INTERCEPT Platelet System to Largest Region of German Red Cross,” is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d) Exhibits

 

99.1    Press Release, dated June 11, 2008, entitled “Cerus Enters Into Agreement to Supply INTERCEPT Platelet System to Largest Region of German Red Cross.”


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CERUS CORPORATION
Dated: June 11, 2008     By:    /s/ William J. Dawson
       

William J. Dawson

Vice President, Finance and Chief Financial Officer


EXHIBIT INDEX

 

Exhibit
Number

  

Description

99.1

   “Cerus Enters Into Agreement to Supply INTERCEPT Platelet System to Largest Region of German Red Cross”